Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN #1401)

Trial Profile

Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN #1401)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Dendritic cell vaccines (Primary) ; Granulocyte macrophage colony stimulating factor (Primary) ; Lenalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms BMT CTN 1401
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top